# Voraxaze for Delayed Methotrexate Clearance

> **NCT00424645** · PHASE1,PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 3 (actual)

## Conditions studied

- Hematologic Malignancy
- Solid Tumor

## Interventions

- **DRUG:** Voraxaze (Glucarpidase)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00424645
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-01
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Sponsor terminated due to low accrual.
- **Last updated:** 2012-12-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00424645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00424645, "Voraxaze for Delayed Methotrexate Clearance". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00424645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*